ID | 61201 |
FullText URL | |
Author |
Yamamoto, Haruchika
Department of Thoracic Surgery, Okayama University Hospital
Yamamoto, Hiromasa
Department of Thoracic Surgery, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Soh, Junichi
Department of Thoracic Surgery, Okayama University Hospital
Suzuki, Etsuji
Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Namba, Kei
Department of Thoracic Surgery, Okayama University Hospital
Miyoshi, Kentaroh
Department of Thoracic Surgery, Okayama University Hospital
Kaken ID
Otani, Shinji
Department of Thoracic Surgery, Okayama University Hospital
Okazaki, Mikio
Department of Thoracic Surgery, Okayama University Hospital
Sugimoto, Seiichiro
Department of Thoracic Surgery, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Yorifuji, Takashi
Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Takahashi, Katsuhito
Center for Multidisciplinary Treatment of Sarcoma, Department of Sarcoma Medicine, Kameda Medical Center
Toyooka, Shinichi
Department of Thoracic Surgery, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
Abstract | Background
Pulmonary metastasectomy could be considered one of the treatment options for disease control in sarcoma patients with pulmonary metastases; however, there is little consensus regarding the suitable criteria for predicting the likely outcomes in these patients. The aim of this study was to establish a prognostic benefit scoring system based on preoperatively examined prognostic factors for sarcoma patients with pulmonary metastases.
Methods
This was a single-center, retrospective cohort study conducted in a cohort of 135 sarcoma patients who underwent a first pulmonary metastasectomy at Okayama University Hospital between January 2006 and December 2015. Based on the results of a multivariable logistic regression analysis performed to determine the factors influencing 3-year mortality, a Sarcoma Lung Metastasis Score was created and its correlation with 3-year survival was analyzed.
Results
The results of the multivariate analysis revealed significant differences in the disease-free interval (< 2 years vs. ≥ 2 years; odds ratio (OR) 4.22, 95% confidence interval (CI) 1.67–10.70), maximum tumor diameter (≥ 15 mm vs. < 15 mm; OR 3.86, 95% CI 1.75–8.52), and number of pulmonary metastases (≥ 6 vs. < 6; OR 2.65, 95% CI 1.06–6.620). The Sarcoma Lung Metastasis Score, which was defined as the total score of these three factors, reliably predicted 3-year survival (score: 0, 89.5%; 1, 63.2%; 2, 39.0%; 3, 10.5%).
Conclusions
Our newly proposed simple Sarcoma Lung Metastasis Score appears to be a useful prognostic predictor for sarcoma patients with pulmonary metastases, in that it could be helpful for the selection of appropriate treatments for these patients.
|
Note | This is a post-peer-review, pre-copyedit version of an article published in Annals of Surgical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1245/s10434-020-09272-1.
|
Published Date | 2020-11-24
|
Publication Title |
Annals of Surgical Oncology
|
Volume | volume28
|
Publisher | Springer
|
Start Page | 3884
|
End Page | 3890
|
ISSN | 1068-9265
|
NCID | AA11016573
|
Content Type |
Journal Article
|
language |
English
|
File Version | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1245/s10434-020-09272-1
|